CFT7455: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023. CFT8634: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial in the second half of 2023 in synovial sarcoma and SMARCB1-null solid tumors. CFT1946: Continue site activation and patient enrollment of the dose escalation portion of the CFT1946 Phase 1/2 clinical trial in BRAF V600 mutant solid tumors. Present new preclinical data on the discovery and characterization of CFT1946 at 2023 AACR Annual Meeting in April. CFT8919: Submit an Investigational New Drug application for CFT8919 for the treatment of NSCLC in the first half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
- C4 Therapeutics to Present at Two Virtual February 2023 Conferences
- C4 Therapeutics announces first patient dosed in Phase 1/2 trial of CFT1946
- C4 Therapeutics expects cash to fund operations to end of 2024
- C4 Therapeutics announces 2023 strategic priorities